Infliximab (Remicade, Centocor) has been approved for children with active Crohn’s disease, a chronic, inflammatory bowel condition.
This genetically engineered monoclonal antibody reduces inflammation by blocking the action of tumor necrosis factor-alpha (TNF-a). The agent was initially approved in 1998 to treat Crohn’s disease in adults. cheap cialis canadian pharmacy
The drug’s safety and effectiveness were assessed in a randomized study of 112 children, 6 to 17 years of age, who had not responded adequately to conventional therapies. The proportion of patients achieving clinical responses compared favorably with that of adults in an earlier study. The pediatric trial showed no new safety concerns not already expressed in the product’s current label.